FBIO · Fortress Biotech, Inc. · Metrics
$1.93
+0.06 (+3.21%)
At close · Oct 27
Return incl. dividend (before tax)
Q3 2025 earnings call transcript
Market Cap
$68.78M
Shares
36.78M
Volume · Oct 27
157.14K
Avg daily vol (3M)
418.62K
FBIO metrics
80 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$1.93
Market cap
$68.78M
Price action
20 metricsPrice change (1W)
+0.0%
Price change (30D)
-13.8%
Price change (3M)
-42.8%
Price change (6M)
-17.6%
Price change (YTD)
-48.9%
Price change (1Y)
-25.5%
Trailing year
Price change (5Y)
—
52-week high
$4.38
52-week low
$1.87
Change from 52-week high
-57.3%
Change from 52-week low
+0.0%
Annualized volatility
63.2%
Annualized volatility (3M)
50.0%
Beta
1.1
RSI (14D)
31.3
Price vs SMA 50
-21.4%
Price vs SMA 200
-33.9%
Avg volume (3M)
422,557
Relative volume
0.3
Average dollar volume
$1.12M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
36.78M
Valuation
12 metricsP / E (TTM)
0.7
Trailing earnings · reciprocal yield 144.4%
PEG ratio
—
EV / revenue
-1.4×
EV / EBITDA
—
EV / EBIT
—
P / sales
1.0×
reciprocal yield 99.6%
P / book
0.4
reciprocal yield 238.7%
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
0.5
reciprocal yield 183.1%
Earnings yield
162.6%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.3×
reciprocal yield 43.7%
EV / revenue historical average (5Y)
2.3×
reciprocal yield 43.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2025-11-14
Profitability
9 metricsGross margin
65.6%
Operating margin
-42.6%
Trailing 12 months
Net margin
163.3%
Gross profit (TTM)
$44.91M
Operating profit (TTM)
−$29.18M
Net income (TTM)
$111.82M
Trailing 12 months
Diluted EPS (TTM)
$2.70
FCF margin
—
Effective tax rate
3.3%
Growth
11 metricsRevenue growth YoY
+14.0%
Year over year
Net income growth YoY
-103.0%
Revenue (TTM)
$68.47M
Trailing 12 months
EPS growth YoY
-117.8%
Shares change YoY
+6.6%
Year over year · more shares
Revenue CAGR (3Y)
-5.8%
Revenue CAGR (5Y)
+6.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
68.1%
Return on assets
35.3%
Debt / equity
0.2
Current ratio
4.0
EBITDA (TTM)
−$83.94M
Free cash flow (TTM)
—
Quick ratio
3.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
-1,100.3%
Trailing 12 months
Net cash
$161.58M
Latest balance sheet
Cash & equivalents
$196.58M
Total assets
$316.71M
Total debt
$35.00M
Cash flow & spend
7 metricsOperating cash flow (TTM)
$125.92M
Capital expenditures (TTM)
$0
R&D (TTM)
$1.18M
SG&A (TTM)
$68.68M
Stock compensation (TTM)
$10.29M
R&D / revenue
1.7%
Stock compensation / revenue
15.0%
Ownership (13F)
9 metrics13F filers
55
13F filer change QoQ
+2
Institutional ownership
17.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+10.8%
Holder tenure
6.4
Price vs estimated holder cost
+13.3%
Ownership (registered funds)
1 metricsIndex-fund ownership
3.6%
Short interest
3 metricsShort interest
12.3%
Latest settlement · 16.1 days to cover
Days to cover
16.1d
Short-squeeze score
65 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—